The mechanism of comparable serum cholesterol lowering effects of pravastatin sodium, a 3-hydroxy-3-methylgutaryl coenzyme a inhibitor, between once- and twice-daily treatment regimens in beagle dogs and rabbits

Japanese Journal of Pharmacology

Volumn 70, Issue 4, 1996, Pages 329-335

  Fujioka, Tomoyuki ^a   Nara, Futoshi ^a   Shimada, Yoko ^a   Fukushige, Junichiro ^a   Shimotsu, Hidenori ^a   Shigehara, Eiji ^a   Fukami, Masaharu ^b   Tsujita, Yoshio ^a  

^a DAIICHI SANKYO CO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Dosing regimen; Hepatocyte (rabbit); Immunoblotting; Low density lipoprotein (LDL) receptor; Pravastatin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CHOLESTEROL; ENZYME INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHOLIPID; PRAVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DOG; IMMUNOBLOTTING; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOSPHOLIPID BLOOD LEVEL; RABBIT; RECEPTOR DENSITY; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; BINDING, COMPETITIVE; CELLS, CULTURED; CHOLESTEROL; DISEASE MODELS, ANIMAL; DOGS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOBLOTTING; IODINE RADIOISOTOPES; ISOTOPE LABELING; LIVER; MALE; PRAVASTATIN; RABBITS; RECEPTORS, LDL; SPECIES SPECIFICITY; UP-REGULATION;

EID: 0029918216     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.70.329     Document Type: Article

References (29)

1. Mabuchi H, Sakai T, Yoshimura A, Watanabe A, Wakasugi T, Koizumi J and Takeda R: Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. N Engl J Med 308, 609-613 (1983)
2. Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I, Tanaka M, Masuda H, Tarumi T, Watanabe Y and Fujii S: CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 877, 50-60 (1986)
3. Illingworth DR: Lipid-lowering drugs. An overview of indications and optimum therapeutic use. Drugs 33, 259-279 (1987)
4. Saito Y, Goto Y, Nakaya N, Hata Y, Homma Y, Naito C, Hayashi H, Ito H, Yamamoto M, Shirai K, Sasaki N, Shinomiya M, Murano S, Morisaki N, Nishiide T, Kanzaki T, Watanabe N and Ishikawa T: Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. Atherosclerosis 723, 205-211 (1988)
5. Grundy SM: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319, 24-33 (1988)
6. Hunninghake DB: HMG-CoA reductase inhibitors. Curr Opin Lipidol 3, 22-28 (1992)
7. Reihner E, Rudling M, Stahlberg D, Berglund L, Ewerth S, Bjorkem I, Einarsson K and Angelin B: Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 323, 224-228 (1990)
8. Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M and Kuroda M: The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta 1254, 7-12 (1995)
9. Kuroda M, Matsumoto A, Itakura H, Watanabe Y, Ito T, Shiomi M, Fukushige J, Nara F, Fukami M and Tsujita Y: Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits. Jpn J Pharmacol 59, 65-70 (1992)
10. Roach PD, Kerry NL, Whiting MJ and Nestel PJ: Coordinate changes in the low density lipoprotein receptor activity of liver and mononuclear cells in the rabbit. Atherosclerosis 101, 157-164 (1993)
11. Kume N, Kita T, Mikami A, Yokode M, Ishii K, Nagano Y and Kawai C: Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (pravastatin) and cholestyramine. Circulation 79, 1084-1090 (1989)
12. Kovanen PT, Bilheimer DW, Goldstein JL, Jaronimo JJ and Brown MS: Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA 78, 1194-1198 (1981)
13. Hunninghake DB, Mellies MJ, Goldberg AC, Kuo PT, Kostis JB, Schrott HG, William I Jr and Pan HY: Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 85, 219-227 (1990)
14. Pan HY, Devault AR, Brescia D and Willard DA: Comparative efficacy of once-daily versus twice-daily pravastatin in primary hypercholesterolemia. Clin Ther 6, 368-372 (1991)
15. Pan HY: Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol 40, Supp 1, S15-S18 (1991)
16. Serizawa N, Nakagawa K, Hamano K, Tsujita Y and Kuwano H: Microbial hydroxylation of ML-236B (Compactin) and Monacolin K (MB-530B). J Antibiot 36, 604-607 (1983)
17. Hatch FT and Lees RS: Practical method for plasma lipoprotein analysis. Adv Lipid Res 6, 1-68 (1968)
18. Selgen PO: Preparation of isolated rat liver cells. Methods Cell Biol 13, 29-83 (1976)
19. Macfarlane AS: Efficient trace-labelling of proteins with iodine. Nature 182, 53 (1958)
20. Goldstein JL, Basu SK, Brunschede GY and Brown MS: Release of low density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans. Cell 7, 85-95 (1976)
21. Cosgrove PG, Gaynor BJ and Harwood HJ Jr: Measurement of total hepatic density lipoprotein receptor levels in the hamster. J Lipid Res 34, 1983-2003 (1993)
22. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685 (1970)
23. Beisiegel U, Schneider WJ, Brown MS and Goldstein JL: Immunoblot analysis of low density lipoprotein receptors in fibroblasts from subjects with familial hypercholesterolemia. J Biol Chem 257, 13150-13156 (1982)
24. Parker TS, McNamara DJ, Brown C, Garrigan Q, Kolb R, Batwin H and Ahrens EH Jr: Mevalonic acid in human plasma: Relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci USA 79, 3037-3041 (1982)
25. Havel RJ, Hunninghake DB, Illingworth DR, Lees RS, Stein EA, Tobert JA, Bacon SR, Bolognese JA, Frost PH, Lamkin GE, Lees AM, Leon AS, Gardner K, Johnson G, Mellies MJ, Rhymer PA and Tun P: Lovastatin (meveinolin) in the treatment of heterozygous familial hypercholesterolemia. Ann Intern Med 107, 609-615 (1987)
26. Illingworth DR: Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia. Clin Pharmacol Ther 40, 338-343 (1986)
27. Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E and Tanaka M: Diposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmacokinet 17, 103-113 (1992)
28. Tam S-P, Brissette L, Ramharack R and Deeley RG: Differences between the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor in human hepatoma cells and fibroblasts reside primarily at the transcriptional and post-transcriptional levels. J Biol Chem 266, 16764-16773 (1991)
29. Ma PTS, Gil G, Sudhof TC, Bilheimer DW, Goldstein JL and Brown MS: Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 83, 8370-8374 (1986)